Enthusiasm for the use of selective COX-2 blocking agents in the chemoprevention of colon cancer and other malignancies has been tempered by reports of adverse effects on the cardiovascular system leading to the recall of the popular anti-arthritic compound, rofecoxib (Vioxx) [23-25], and subsequently, the cardiovascular safety of all selective COX-2 inhibitors has come under scrutiny [5]. Here, PTGS2 is linked to colonic neoplasm.